A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
CorMedix Inc.
CRMD
$629M
Mkt Cap
$7.87
-2.24%
CorMedix Inc. (CRMD) has a current P/E ratio of 4.7.
CorMedix Inc. (CRMD) has a 5-year average return on invested capital (ROIC) of -16.8%. This is below average and may indicate limited pricing power.
CorMedix Inc. (CRMD) has a market capitalization of $629M. It is classified as a small-cap stock.
CorMedix Inc. (CRMD) does not currently pay a regular dividend.
CorMedix Inc. (CRMD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CorMedix Inc. (CRMD) reported annual revenue of $312 million in its most recent fiscal year, based on SEC EDGAR filings.
CorMedix Inc. (CRMD) has a net profit margin of 52.3%. This is a strong margin indicating high profitability.
CorMedix Inc. (CRMD) generated $173 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CorMedix Inc. (collectively, with our wholly owned subsidiaries, referred to herein as “we,” “us,” “our” or the “Company”) is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Our primary focus has been commercializing DefenCath® (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis setting. The name DefenCath is the U.S. proprietary name approved by the U.S. Food and Drug Administration (“FDA”).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 312M | 312M | 43M | - | - | - |
| Net Income | 163M | 163M | -18M | -46M | -30M | -28M |
| EPS | $2.04 | $2.04 | $-0.30 | $-0.91 | $-0.74 | $-0.75 |
| Free Cash Flow | 173M | 173M | -51M | -39M | -25M | -23M |
| ROIC | 61.5% | 101.9% | -21.2% | -66.1% | -53.9% | -44.9% |
| Gross Margin | 77.3% | 77.3% | 34.0% | - | - | - |
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 150M | 150M | -22M | -49M | -31M | -29M |
| Operating Margin | 48.2% | 48.2% | -51.4% | - | - | - |
| ROE | 40.2% | 66.6% | -21.2% | -66.1% | -53.9% | -44.9% |
| Shares Outstanding | 80M | 80M | 60M | 51M | 40M | 38M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 43M | 312M | 312M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 34.0% | 77.3% | 77.3% |
| R&D | 1.3M | 6.3M | 16M | 24M | 19M | 11M | 13M | 13M | 11M | 13M | 3.9M | 19M | 19M |
| SG&A | 7.3M | 10M | 8.9M | 8.7M | 8.1M | 9.9M | 14M | 16M | 20M | 36M | 30M | 68M | 68M |
| EBIT | -8.9M | -17M | -25M | -33M | -27M | -21M | -27M | -29M | -31M | -49M | -22M | 150M | 150M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -51.4% | 48.2% | 48.2% |
| Net Income | -21M | -18M | -25M | -33M | -27M | -44M | -22M | -28M | -30M | -46M | -18M | 163M | 163M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -41.2% | 52.3% | 52.3% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -138.0% | -96.8% | -95.1% | -193.3% | -112.7% | -146.2% | -49.8% | -44.9% | -53.9% | -66.1% | -21.2% | 101.9% | 61.5% |
| ROE | -565.0% | -96.8% | -95.1% | -458.9% | -543.7% | -184.1% | -49.8% | -44.9% | -53.9% | -66.1% | -21.2% | 66.6% | 40.2% |
| ROA | -509.2% | -86.4% | -83.5% | -245.4% | -142.5% | -147.7% | -44.7% | -40.9% | -47.9% | -56.5% | -15.1% | 34.5% | 19.7% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -6.3M | -13M | -22M | -29M | -24M | -15M | -22M | -21M | -24M | -38M | -51M | 175M | 175M |
| Free Cash Flow | -6.3M | -13M | -22M | -29M | -24M | -15M | -22M | -23M | -25M | -39M | -51M | 173M | 173M |
| Owner Earnings | -8.5M | -16M | -24M | -30M | -25M | -18M | -25M | -26M | -29M | -44M | -57M | 147M | 147M |
| CapEx | 25K | 15K | 59K | 152K | 49K | 37K | 113K | 1.4M | 219K | 327K | 116K | 2.3M | 2.3M |
| Maint. CapEx | 15K | 15K | 26K | 37K | 74K | 73K | 128K | 62K | 85K | 71K | 310K | 15M | 15M |
| Growth CapEx | 10K | 0 | 33K | 115K | 0 | 0 | 0 | 1.4M | 135K | 257K | 0 | 0 | 0 |
| D&A | 15K | 15K | 26K | 37K | 74K | 73K | 128K | 62K | 85K | 71K | 310K | 15M | 15M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.3% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 2.2M | 3.2M | 1.3M | 1.7M | 1.1M | 2.4M | 2.5M | 5.0M | 4.1M | 5.5M | 6.1M | 14M | 14M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -4.3M | N/A | N/A | -12M | -29M | -22M | -45M | -65M | -58M | -75M | -51M | -144M | -140M |
| Cash & Equiv. | 4.3M | 12M | 8.1M | 10M | 18M | 16M | 42M | 53M | 43M | 44M | 41M | 145M | 145M |
| Long-Term Debt | 0 | N/A | N/A | 0 | 6.1M | 6.1M | N/A | N/A | N/A | N/A | N/A | 586K | 586K |
| Debt/Equity | 0.00 | 0.09 | 0.23 | 0.00 | 1.24 | 0.26 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest Coverage | -4265.5 | -4201.3 | -18887.0 | -5859.4 | -14342.9 | -26.7 | -819.3 | -1846.4 | -1155.0 | -1427.5 | -621.0 | 54.0 | 54.0 |
| Equity | 3.6M | 34M | 18M | 7.2M | 4.9M | 24M | 44M | 63M | 55M | 70M | 85M | 405M | 405M |
| Total Assets | 5.1M | 37M | 22M | 13M | 19M | 29M | 49M | 69M | 62M | 82M | 119M | 826M | 826M |
| Total Liabilities | 1.5M | 3.1M | 4.1M | 6.3M | 14M | 5.8M | 5.1M | 6.1M | 7.0M | 12M | 34M | 421M | 421M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.8M | 379M | 379M |
| Retained Earnings | -76M | -94M | -119M | -152M | -179M | -195M | -217M | -246M | -275M | -322M | -340M | -177M | -177M |
| Working Capital | 3.6M | 34M | 18M | 7.0M | 11M | 24M | 44M | 61M | 53M | 68M | 81M | 193M | 193M |
| Current Assets | 5.0M | 37M | 22M | 13M | 19M | 29M | 48M | 66M | 60M | 79M | 115M | 367M | 367M |
| Current Liabilities | 1.4M | 3.1M | 4.1M | 6.3M | 7.8M | 5.8M | 4.2M | 5.3M | 6.3M | 11M | 34M | 174M | 174M |
| Per Share Data | |||||||||||||
| EPS | -4.80 | -2.90 | -3.25 | -3.00 | -7.55 | -1.80 | -0.77 | -0.75 | -0.74 | -0.91 | -0.30 | 2.04 | 2.04 |
| Owner EPS | -1.99 | -2.51 | -3.12 | -1.27 | -7.00 | -0.73 | -0.86 | -0.70 | -0.71 | -0.86 | -0.95 | 1.83 | 1.83 |
| Book Value | 0.85 | 5.41 | 2.35 | 0.30 | 1.39 | 0.98 | 1.55 | 1.67 | 1.37 | 1.38 | 1.42 | 5.07 | 5.07 |
| Cash Flow/Share | -1.48 | -1.99 | -2.94 | -1.20 | -6.67 | -0.62 | -0.77 | -0.56 | -0.61 | -0.75 | -0.85 | 2.19 | 2.22 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 4.3M | 6.3M | 7.6M | 23.8M | 3.6M | 24.2M | 28.6M | 37.6M | 40.1M | 50.9M | 59.8M | 79.9M | 79.9M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.9 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.6 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.3 |
| Price/Book | 9.9 | 1.9 | 3.4 | 19.9 | 115.1 | 7.3 | 4.8 | 3.3 | 3.1 | N/A | 5.8 | N/A | 1.6 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 8.2 | N/A | 2.0 |
| FCF Yield | -17.7% | -19.5% | -36.6% | -20.1% | -4.2% | -8.7% | -10.4% | -10.9% | -14.6% | N/A | -10.3% | N/A | 27.5% |
| Market Cap | 36M | 64M | 61M | 143M | 568M | 173M | 213M | 207M | 169M | 0 | 491M | 0 | 629M |
| Avg. Price | 9.40 | 21.15 | 11.14 | 4.51 | 3.06 | 7.81 | 5.52 | 7.31 | 4.01 | 0.00 | 5.99 | 0.00 | 7.87 |
| Year-End Price | 8.40 | 10.25 | 8.05 | 2.60 | 6.35 | 7.14 | 7.45 | 4.65 | 3.79 | 0.00 | 8.21 | 0.00 | 7.87 |
CorMedix Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 55.6%.
CorMedix Inc. (CRMD) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
CorMedix Inc. (CRMD) reported earnings per share (EPS) of $2.04 in its most recent fiscal year.
CorMedix Inc. (CRMD) has a return on equity (ROE) of 66.6%. This indicates the company generates strong returns for shareholders.
CorMedix Inc. (CRMD) has a 5-year average gross margin of 55.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for CorMedix Inc. (CRMD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CorMedix Inc. (CRMD) has a book value per share of $5.07, based on its most recent annual SEC filing.